Renascience Inc. (JP:4889)

:4889

4889

Renascience Inc.

RESEARCH TOOLSreports

Renascience Inc. (4889) Price & Analysis

Compare

0 Followers

4889 Stock Chart & Stats

¥1436.00

-¥9.00(-2.89%)

At close: Jan 08 4:00 PM EST

¥1436.00

-¥9.00(-2.89%)

Day’s Range― - ―

52-Week Range¥868.00 - ¥3,310.00

Previous CloseN/A

Volume77.30K

Average Volume (3M)312.67K

Market Cap

¥23.31B

Enterprise Value¥19.51B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.79

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.21

Shares Outstanding13,513,500

10 Day Avg. Volume205,420

30 Day Avg. Volume312,670

Financial Highlights & Ratios

PEG Ratio-0.82

Price to Book (P/B)7.74

Price to Sales (P/S)100.40

P/FCF Ratio-75.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet with a ¥1.72B equity base materially reduces refinancing and interest-rate risk, giving management structural financial flexibility to fund R&D, clinical programs, or partner deals without near-term solvency pressure, supporting multi-quarter durability.

Improved Profitability And High Gross MarginTransition to positive net income combined with an extremely high gross margin implies strong product economics or favorable cost structure. If sustainable, these margins enable scalable profits as revenue stabilizes, improving long-term return potential and funding capacity for growth initiatives.

Lean Operating StructureA very small headcount indicates a lean operating model that can limit fixed overhead and extend runway relative to peers. For a biotech developer, this structural efficiency helps conserve capital between financing or milestone events, preserving flexibility over multiple quarters.

Bears Say

Persistent Cash BurnNegative operating and free cash flow despite reported net income signals weak cash conversion and ongoing burn. This structural cash deficit requires recurring external funding or asset monetization, creating dilution or financing risk over the next several quarters if operations don't generate positive cash.

Declining Revenue TrendA falling top line and multi-period revenue deterioration reduce the durability of recent profitability gains. Structural revenue weakness constrains margin leverage, limits internal funding for programs, and increases dependence on one-off gains or financing to sustain operations over the medium term.

Uneven Earnings QualityProfitability appears uneven and partly non-recurring: several prior years of losses and a modest FY2025 ROE suggest earnings may not be repeatable. Reliance on below-the-line items or one-off gains undermines confidence in sustainable operating performance and complicates long-term planning.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥868.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥23.31B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is May 07, 2026 which is in 39 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Feb 13, 2026. The company reported -¥5.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.21.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,513,500 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.626%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.